<DOC>
	<DOCNO>NCT00478218</DOCNO>
	<brief_summary>RATIONALE : Lenalidomide may stop growth multiple myeloma block blood flow cancer . Drugs use chemotherapy , cyclophosphamide dexamethasone , work different way stop growth cancer cell , either kill cell stop divide . Giving lenalidomide together cyclophosphamide dexamethasone may kill cancer cells. &gt; PURPOSE : This phase II trial study well give lenalidomide together cyclophosphamide dexamethasone work treat patient newly diagnose multiple myeloma .</brief_summary>
	<brief_title>Lenalidomide , Cyclophosphamide , Dexamethasone Treating Patients With Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary * Assess response rate patient newly diagnose active multiple myeloma treat lenalidomide , cyclophosphamide , dexamethasone . Secondary - Assess toxicity regimen patient . - Determine time progression patient treat regimen . OUTLINE : Patients receive oral lenalidomide day 1-21 , oral cyclophosphamide day 1 , 8 , 15 , oral dexamethasone day 1 , 8 , 15 , 22 . Treatment repeat every 28 day 4-12 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 6 month 5 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma Newly diagnose disease Symptomatic disease Measurable evaluable disease , define ≥ 1 follow criterion : Serum monoclonal protein ≥ 1.0 g protein electrophoresis Monoclonal protein &gt; 200 mg 24hour urine electrophoresis Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum immunoglobulin kappa lambda free light chain ratio Monoclonal bone marrow plasmacytosis ≥ 30 % ( evaluable disease ) Measurable soft tissue plasmacytoma previously irradiate No monoclonal gammopathy undetermined significance smolder myeloma PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 ( ECOG PS 3 allow secondary pain ) ANC ≥ 1,500/mm^3 Platelet count ≥ 75,000/mm^3 Hemoglobin ≥ 8.0 g/dL Creatinine ≤ 2.5 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublemethod contraception ( 1 highly effective 1 additional method ) 1 month , , 4 week completion study therapy No uncontrolled infection No active malignancy No malignancy within past 5 year except currently treat basal cell squamous cell carcinoma skin carcinoma situ cervix breast No NYHA class IIIIV congestive heart failure No untreated active deep vein thrombosis PRIOR CONCURRENT THERAPY : At least 3 week since prior radiotherapy solitary plasmacytoma Prior clarithromycin , therapeutic dehydroepiandrosterone ( DHEA ) , anakinra , pamidronate disodium , zoledronic acid allow No prior cytotoxic chemotherapy No prior corticosteroid ( except treatment nonmalignant disorder ) Concurrent corticosteroid ( prednisone ≤ 20 mg/per day ) allow No concurrent radiotherapy except palliative radiotherapy single painful bone lesion fracture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>